title: Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
abstract: BACKGROUND
  Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination.
  
  
  METHODS
  To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy.
  
  
  RESULTS
  Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups.
  
  
  CONCLUSIONS
  Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.
authors: Department of Hematology and Oncology, Kyushu University Hospital, Fukuoka, Japan E-mail : e-baba@c-oncology.med.kyushu-u.ac.jp.
authors: Hozumi
authors: H
authors: Kumagai
authors: Hitoshi
authors: H
authors: Kusaba
authors: Yuta
authors: Y
authors: Okumura
authors: Masato
authors: M
authors: Komoda
authors: Michitaka
authors: M
authors: Nakano
authors: Shingo
authors: S
authors: Tamura
authors: Mayako
authors: M
authors: Uchida
authors: Kenichiro
authors: K
authors: Nagata
authors: Shuji
authors: S
authors: Arita
authors: Hiroshi
authors: H
authors: Ariyama
authors: Shigeo
authors: S
authors: Takaishi
authors: Koichi
authors: K
authors: Akashi
authors: Eishi
authors: E
authors: Baba
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects; D000077608:Aprepitant; D001562:Benzimidazoles / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D017829:Granisetron / Q000627:therapeutic use; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use; D007564:Japan; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D000077924:Palonosetron; D011812:Quinuclidines / Q000627:therapeutic use; D012189:Retrospective Studies; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D000077608:Aprepitant; D001562:Benzimidazoles; D003907:Dexamethasone; D017829:Granisetron; D007546:Isoquinolines; D009025:Morpholines; D000077924:Palonosetron; D011812:Quinuclidines; D012702:Serotonin Antagonists; C579707:fosaprepitant; C071315:ramosetron